Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


SpectraMax® i3: When is the last time you inspected your cells and ran an assay on the same instrument?

Product Image
Product Description

The SpectraMax® i3 is Molecular Devices latest multi-mode microplate reader which delivers several applications including; Ultra-Violet to visible absorbance detection, fluorescence intensity and multi-colour luminescence. There is the option to add user-installable cartridges as your research needs evolve including HTRF®, AlphaScreen® and Fluorescence Polarisation assays as well as cellular imaging, (with the SpectraMax® MiniMax™) increasing the instruments flexibility. This highly sensitive instrument accommodates the budget and throughput needs of both small and large laboratories alike.

The SpectraMax® i3 Platform's base system features an integrated optical system which enables both top and bottom reads for 6-, 384- well microplates and launches with three broad detection modes: luminescence, absorbance, and fluorescence. The patented user-exchangeable cartridge design expands the system's detection capability making it highly versatile, and able to offer application options far exceeding those of standard readers.

Using a combination of a flash lamp for spectral flexibility and light emitting diodes (LEDs) for excitation power, Molecular Devices has developed the patent-pending Spectral Fusion™ Illumination to deliver wavelength flexibility whilst maximizing signal strength, ultimately increasing overall performance.

Data from the SpectraMax® i3 System is captured and analysed using Molecular Devices' proprietary, industry-leading SoftMax® Pro Software. The newly updated interface and Spectral Optimization Wizard simplifies the workflow and provides powerful data analysis features, eliminating the need for training on additional software. The SpectraMax® i3 System is also available for use in GMP and GLP labs when used with the SoftMax® Pro 6.3 GxP Microplate Data Compliance Software. This new user interface and powerful data analysis package simplifies the set-up of the SpectraMax® i3 platform, getting you to your results much faster!

SpectraMax® MiniMax™ Imaging Cytometer

When is the last time you inspected your cells and ran an assay on the same instrument? With the user-upgradable imaging cytometer option, turn your SpectraMax® i3 microplate reader into a cellular imager and unlock a new world of applications. 

The MiniMax™ Imaging Cytometer module adds first of its kind cellular imaging to a multi-mode detection platform, enabling fluorescence and bright field cellular imaging. Combining cellular imaging with microplate-based applications offers new ways for scientists to compress their workflows and increase efficiency. 

Key benefits include:

User Upgradeability:
Expand the 3-mode base system with additional application cartridges for FP, HTRF®, AlphaScreen® assays and cellular imaging. These user-installable cartridges prevent the need for system down time or service engineers. 

SpectraMax® MiniMax™ Imaging Cytometer:
Simplifies complex imaging workflows by visualising cell morphology changes on top of well-based intensity readings

Spectral Fusion™ Illumination:
Delivers high-powered full spectrum light source for increased fluorescence performance across the entire excitation range

Expanded Dynamic Range:
Sophisticated engineering delivers optimal sensitivity and maximises signal range 

Imagine the SpectraMax® i3 in your lab today and begin to realise what this system will bring to your research!

For more information on the SpectraMax® i3 and SpectraMax® MiniMax™ and to see a video of them in action CLICK HERE

Product SpectraMax® i3: When is the last time you inspected your cells and ran an assay on the same instrument?
Company Molecular Devices
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Molecular Devices
660 - 665 Eskdale Road Winnersh Triangle Wokingham Berkshire RG41 5TS

Tel: +44-118-944-8000
Fax: +44-118-944-8001
Email: infoboxeu@moldev.com



Scientific News
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.

SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!